Guohua Sun1, Yu Wang, Yongxue Zhu, Caiping Huang, Qinghai Ji. 1. Department of Head & Neck Surgery, Fudan University Shanghai Cancer Center and Department of Oncology, Shanghai Medical College, Fudan University, Shanghai, China.
Abstract
CONCLUSION: Duffy antigen receptor for chemokines (DARC), as a negative regulator, could attenuate the potential growth and metastasis of laryngeal squamous cell carcinoma (LSCC); hence it could be considered as a basis for a new prognostic aid and molecular therapeutic target in treating LSCC. OBJECTIVES: To analyze the role of DARC in LSCC progression using LSCC clinical samples. METHODS: A total of 65 LSCC tissues were examined immunohistochemically for DARC protein expression. The microvessel density (MVD) was determined by the endothelial cells immunostained using anti-CD34 antibody. RESULTS: It was found that DARC was expressed in the LSCC samples, with a high expression in 32 of our cases (49.2%), and in lymph node-negative and -positive groups of 24 (72.7%) and 8 cases (25%), respectively (p < 0.01). MVD was (24.75 ± 5.45)/High power field (HP) and (32.58 ± 5.23)/HP in the cases with high and low expression of DARC, respectively (p < 0.01). More importantly, the DARC expression presented a strong negative correlation with nodal metastasis, with pTNM stage, and with recurrence, and the cases with a high DARC expression indicated a higher survival rate. In addition, the multivariate analysis showed that the DARC expression was an independent prognostic factor (p = 0.032; hazard ratio, 21.476; 95% confidence interval, 1.297-355.68).
CONCLUSION: Duffy antigen receptor for chemokines (DARC), as a negative regulator, could attenuate the potential growth and metastasis of laryngeal squamous cell carcinoma (LSCC); hence it could be considered as a basis for a new prognostic aid and molecular therapeutic target in treating LSCC. OBJECTIVES: To analyze the role of DARC in LSCC progression using LSCC clinical samples. METHODS: A total of 65 LSCC tissues were examined immunohistochemically for DARC protein expression. The microvessel density (MVD) was determined by the endothelial cells immunostained using anti-CD34 antibody. RESULTS: It was found that DARC was expressed in the LSCC samples, with a high expression in 32 of our cases (49.2%), and in lymph node-negative and -positive groups of 24 (72.7%) and 8 cases (25%), respectively (p < 0.01). MVD was (24.75 ± 5.45)/High power field (HP) and (32.58 ± 5.23)/HP in the cases with high and low expression of DARC, respectively (p < 0.01). More importantly, the DARC expression presented a strong negative correlation with nodal metastasis, with pTNM stage, and with recurrence, and the cases with a high DARC expression indicated a higher survival rate. In addition, the multivariate analysis showed that the DARC expression was an independent prognostic factor (p = 0.032; hazard ratio, 21.476; 95% confidence interval, 1.297-355.68).
Authors: Dorota Smolarek; Claude Hattab; Anna Buczkowska; Radoslaw Kaczmarek; Anna Jarząb; Sylvie Cochet; Alexandre G de Brevern; Jolanta Lukasiewicz; Wojciech Jachymek; Tomasz Niedziela; Magdalena Grodecka; Kazimiera Wasniowska; Yves Colin Aronovicz; Olivier Bertrand; Marcin Czerwinski Journal: PLoS One Date: 2015-02-23 Impact factor: 3.240